Virt-Phos 250 Neutral Ingredients & Drug Interactions
What is this page for?
First and foremost: checking Virt-Phos 250 Neutral against your medications. The heart of this page is the interaction checker and the full interaction report — how this product’s ingredients may interact with prescription and over-the-counter medicines you may be taking.
Around that, we add a pharmacist’s high-level view of the product as a whole — what’s inside, the evidence for its stated use, how transparent the label is, and what safety data exists — so you can see the full picture in one place. It’s educational information from our licensed clinical databases and the clinical staff at HelloPharmacist — not medical advice — and we don’t sell or endorse products. Our editorial policy
Virt-Phos 250 Neutral is a dietary supplement by Virtus Pharmaceuticals with 3 active ingredients. Its ingredients are commonly taken for low blood phosphate levels (hypophosphatemia), bowel preparation/laxative use, athletic performance ('phosphate loading').Based on those ingredients, 12 medications have a known interaction with it, the most serious rated major. The ingredients most likely to interact are Monobasic Potassium Phosphate. Use the checker below to test your specific medication, or read the full HelloPharmacist Interaction Report.
Check Your Meds Against Virt-Phos 250 Neutral by Virtus Pharmaceuticals
Ask about any prescription or over-the-counter medication and we check it for interactions with Virt-Phos 250 Neutral by Virtus Pharmaceuticals — and tell you which ingredient is responsible.
AI summaries are generated from our interaction database for education only — always confirm with your pharmacist. How we use AI
Ask the Pharmacist
A licensed pharmacist will answer your question by email — free, usually within 24 hours.
Got it — thank you!
A licensed pharmacist will answer within 24 hours. Keep an eye on your email (worth checking spam, just in case).
HelloPharmacist Scorecard of Virt-Phos 250 Neutral by Virtus Pharmaceuticals
Our pharmacy team’s full take, with four database checks built into the cards below — a summary of what is known, not a grade of the product itself.
What’s inside
Full disclosure
Virt-Phos 250 Neutral contains 3 active ingredients: two forms of sodium phosphate (dibasic anhydrous and monobasic monohydrate) and monobasic potassium phosphate. These are mineral salts that supply phosphate to your body.
The remaining ingredients are inactive — microcrystalline cellulose, croscarmellose sodium, stearic acid, magnesium stearate, and silicon dioxide — which serve as binders, disintegrants, and flow agents to make the tablet work.
Does it work?
Strong evidence
According to the data we hold, monobasic potassium phosphate (one of the active ingredients here) is Effective for correcting low phosphate levels (hypophosphatemia) and for bowel preparation, and Likely Effective for constipation, upset stomach (dyspepsia), and high blood calcium (hypercalcemia). We don't have effectiveness ratings for the other two ingredients in this product.
How safe is it?
Well-documented data
Phosphate salts are generally well tolerated when used as directed, but the safety notes emphasize that excess can harm your kidneys, heart, and mineral balance. The most common oral side effects are abdominal pain, bloating, diarrhea, nausea, and vomiting.
Rare but serious effects include abnormal calcium deposits outside bone. One important note: sodium phosphate used for bowel cleaning has been linked to acute kidney injury in some patients — risk is higher if you're female, dehydrated, have anemia, or have existing kidney disease.
Regarding pregnancy and lactation, the data shows conflicting ratings: one entry marks phosphate as Likely Safe, while another says Possibly Unsafe. This means there isn't clear consensus, and you should talk with your doctor or pharmacist if you're pregnant or nursing before taking this product.
Meds to double-check
Major interaction found
Before taking this product, double-check with your pharmacist if you're on erdafitinib (Balversa) or futibatinib (Lytgobi) — both carry Major interaction risk and require phosphate restriction. Also check if you take bisphosphonates (such as alendronate/Fosamax), which carry a Moderate risk.
Altogether, these interactions span 12 individual medications.
The bottom line
Scorecard at a glanceFully disclosed formula with clinical evidence supporting its stated purpose. Major medication interactions have been identified, and safety information is well characterized.
Virt-Phos 250 Neutral is used to replace low phosphate or manage certain bowel and digestive issues. If you take erdafitinib, futibatinib, or bisphosphonates, you need to check with your doctor first — these interactions are serious.
Anyone with kidney disease or planning pregnancy should also discuss this with their pharmacist before starting. Run your medications through the checker on this page to be sure.
Educational only — not medical advice; always confirm with your pharmacist. Our editorial policy · How we use AI
Assessment coverage: 1 of 3 active ingredients matched to our full ingredient reviews (monographs). Based on the product label dated Sep 21, 2018.
This Scorecard evaluates available label information, ingredient evidence, and known medication-safety considerations. It does not independently verify product identity, purity, potency, contamination, or manufacturing quality. How these ratings are computed
General information
Key facts about Virt-Phos 250 Neutral, straight from the product label.
| Brand | Virtus Pharmaceuticals |
|---|---|
| Barcode (UPC) | 369543268101 |
| Net contents | 100 Tablet(s) |
| Market status | On market |
| Date entered into DSLD | Sep 21, 2018 |
| DSLD ID | 180560 |
| Product type | Other Combinations |
| Supplement form | Tablet Or Pill |
| Dietary claims / uses | All Other |
| Intended target group(s) | Adult (18 - 50 Years) |
Everything in this section is reproduced from the manufacturer’s own product label — it’s the label speaking, not HelloPharmacist. We show it so you can see exactly what the maker states; we don’t verify or endorse those statements.
Supplement Facts
The label details for Virt-Phos 250 Neutral by Virtus Pharmaceuticals, sourced from the NIH Dietary Supplement Label Database.
Supplement Facts
| Ingredient | Amount | % DV |
|---|---|---|
| Dibasic Sodium Phosphate Anhydrous | 852 mg | -- |
| Monobasic Potassium Phosphate | 155 mg | -- |
| Monobasic Sodium Phosphate Monohydrate | 130 mg | -- |
Other ingredients: Microcrystalline Cellulose, Croscarmellose Sodium, Stearic Acid, Magnesium Stearate, Silicon Dioxide
Tap any ingredient to jump to its full detail below.
These statements are the manufacturer’s wording, reproduced from the product label — the label is saying it, not HelloPharmacist. We don’t verify or endorse them.
General Statements
69543-268-10
Rx Made in USA
FDA Statement of Identity
Prescription Phosphorus Dietary Supplement
Formula
Supplying 250 mg per tablet
Each tablet yields approximately 250 mg (25% DV for adults) of phosphorus. 298 mg sodium (13.0 mEq), and 45 mg of potassium (1.1 mEq).
Description: Virt-Phos 250 Neutral is a prescription phosphorus dietary supplement - supplying 250 mg per tablet for use in the dietary supplement of hypophosphatemia and should be administered under the supervision of a licensed medical practitioner.
Precautions
Allergy: Product may be exposed to tree nuts, peanuts, fish, egg, wheat, milk, soy, and shellfish during manufacture. See prescribing information.
Precautions, contraindications, side effects: See prescribing information.
Keep out of reach of children
Call your licensed medical practitioner about side effects. You may report side effects by calling Vitrus at 1-888-848-3593 or FDA at 1-800-FDA-1088.
Suggested/Recommended/Usage/Directions
Directions for use: Virt-Phos 250 Neutral should be taken with a full glass of water, with meal and at bedtime. Adults: One or two tablets four times daily; Pediatric patients over 4 years of age: One tablet four times daily; Pediatric under 4 years of age: Use only as directed by a licensed healthcare practitioner.
Storage
Storage: Store at 20(0) to 25(0)C (68(0) to 77(0)F). Excursions permitted to 15(0) to 30(0)C (59(0) to 86(0)F). Protect from light and moisture. Dispense in a tight, light-resistant container. Notice: Contact with moisture may product surface discoloration or erosion.
General
Rev. 06/16
Is this label outdated? Report a formula or label change and our pharmacy team will review it.
Virt-Phos 250 Neutral by Virtus Pharmaceuticals label
The label scan from the NIH Dietary Supplement Label Database. Tap to enlarge.
Label images are published by the NIH Dietary Supplement Label Database for the version of this product on file. Always read your actual product label.
View the full label (PDF)The Ingredients in Virt-Phos 250 Neutral by Virtus Pharmaceuticals
These are the 3 active ingredients this product is made of. Select any to open its full monograph.
Serving size1 Tablet(s) Dosage formTablet Or Pill Amounts shown are per serving.
Most supplement products combine several ingredients, and a medication can interact with the product through any one of them. Each ingredient below shows whether it has known drug interactions.
Dibasic Sodium Phosphate Anhydrous
Monobasic Potassium Phosphate
Interacts with12 drugs
Phosphate salts are mineral compounds used mainly to correct low phosphate levels, as laxatives, and sometimes by athletes. Most people who eat a norm...
Monobasic Potassium Phosphate monograph & interactionsMonobasic Sodium Phosphate Monohydrate
Other (inactive) ingredients: Microcrystalline Cellulose, Croscarmellose Sodium, Stearic Acid, Magnesium Stearate, Silicon Dioxide. These complete the product’s ingredient list but are not active constituents.
Virt-Phos 250 Neutral by Virtus Pharmaceuticals Drug Interactions
HelloPharmacist Interaction Report
Virt-Phos 250 Neutral contains phosphate salts that interact with several medications.
The most serious concerns are two targeted cancer drugs: erdafitinib (Balversa) and futibatinib (Lytgobi). Both can raise phosphate levels in your blood, and taking this product with either one significantly increases the risk of high phosphate levels (hyperphosphatemia).
People on these drugs are typically advised to limit phosphate intake to 600–800 mg daily, so you'd need to check with your oncologist before adding this supplement.
Read the full breakdown — every affected drug type, severity by severity
Bisphosphonates (bone-building drugs like alendronate/Fosamax) pose a Moderate interaction risk. Combining phosphate salts with these medications can theoretically lower your blood calcium levels (hypocalcemia), and at least one documented case saw this happen when a patient on alendronate received a large phosphate dose.
We could not check two of the three ingredients in this product — Dibasic Sodium Phosphate Anhydrous and Monobasic Sodium Phosphate Monohydrate — because we hold no monograph data for them. Use the medication checker on this page to verify your exact drugs before starting, and talk with your pharmacist or doctor if you take any of the medications mentioned above.
Check your own medications below · Editorial policy · How we use AI
Want to check YOUR meds against Virt-Phos 250 Neutral?
Ask about interactions with your drugs in plain English — “Can I take it with lisinopril?” — and we find you the answer in seconds, ingredient by ingredient.
Go to the checkerIngredients driving the most interactions
Individual Drug Interactions
The ingredients in Virt-Phos 250 Neutral interact with 12 drugs. Click any drug to see the details.
1 of the 3 ingredients in Virt-Phos 250 Neutral interact with drugs. Each result below shows which ingredient is responsible. Monobasic Potassium Phosphate
ErdafitinibBalversa
How Erdafitinib interacts with Virt-Phos 250 Neutral — through 1 ingredient. Tap an ingredient for the detail:
Monobasic Potassium PhosphateErdafitinib (balversa) Major
Interaction Summary
Taking erdafitinib with phosphate salts increases the risk of hyperphosphatemia.
Read the full Monobasic Potassium Phosphate + Erdafitinib interactionFutibatinibLytgobi
How Futibatinib interacts with Virt-Phos 250 Neutral — through 1 ingredient. Tap an ingredient for the detail:
Monobasic Potassium PhosphateFutibatinib (lytgobi) Major
Interaction Summary
Taking futibatinib with phosphate salts increases the risk of hyperphosphatemia.
Read the full Monobasic Potassium Phosphate + Futibatinib interactionAlendronateBinosto, Fosamax
How Alendronate interacts with Virt-Phos 250 Neutral — through 1 ingredient. Tap an ingredient for the detail:
Monobasic Potassium PhosphateBisphosphonates Moderate
Interaction Summary
Theoretically, taking phosphate salts with bisphosphonates might increase the risk of hypocalcemia.
Read the full Monobasic Potassium Phosphate + Alendronate interactionAlendronate Sodium
How Alendronate Sodium interacts with Virt-Phos 250 Neutral — through 1 ingredient. Tap an ingredient for the detail:
Monobasic Potassium PhosphateBisphosphonates Moderate
Interaction Summary
Theoretically, taking phosphate salts with bisphosphonates might increase the risk of hypocalcemia.
Read the full Monobasic Potassium Phosphate + Alendronate Sodium interactionAlendronate Sodium, CholecalciferolFosamax Plus D
How Alendronate Sodium, Cholecalciferol interacts with Virt-Phos 250 Neutral — through 1 ingredient. Tap an ingredient for the detail:
Monobasic Potassium PhosphateBisphosphonates Moderate
Interaction Summary
Theoretically, taking phosphate salts with bisphosphonates might increase the risk of hypocalcemia.
Read the full Monobasic Potassium Phosphate + Alendronate Sodium, Cholecalciferol interactionEtidronate DisodiumDidrocal, Didronel
How Etidronate Disodium interacts with Virt-Phos 250 Neutral — through 1 ingredient. Tap an ingredient for the detail:
Monobasic Potassium PhosphateBisphosphonates Moderate
Interaction Summary
Theoretically, taking phosphate salts with bisphosphonates might increase the risk of hypocalcemia.
Read the full Monobasic Potassium Phosphate + Etidronate Disodium interactionIbandronateBoniva, Boniva IV
How Ibandronate interacts with Virt-Phos 250 Neutral — through 1 ingredient. Tap an ingredient for the detail:
Monobasic Potassium PhosphateBisphosphonates Moderate
Interaction Summary
Theoretically, taking phosphate salts with bisphosphonates might increase the risk of hypocalcemia.
Read the full Monobasic Potassium Phosphate + Ibandronate interactionPamidronateAredia
How Pamidronate interacts with Virt-Phos 250 Neutral — through 1 ingredient. Tap an ingredient for the detail:
Monobasic Potassium PhosphateBisphosphonates Moderate
Interaction Summary
Theoretically, taking phosphate salts with bisphosphonates might increase the risk of hypocalcemia.
Read the full Monobasic Potassium Phosphate + Pamidronate interactionRisedronateActonel DR
How Risedronate interacts with Virt-Phos 250 Neutral — through 1 ingredient. Tap an ingredient for the detail:
Monobasic Potassium PhosphateBisphosphonates Moderate
Interaction Summary
Theoretically, taking phosphate salts with bisphosphonates might increase the risk of hypocalcemia.
Read the full Monobasic Potassium Phosphate + Risedronate interactionRisedronate SodiumActonel, Actonel Once a Week
How Risedronate Sodium interacts with Virt-Phos 250 Neutral — through 1 ingredient. Tap an ingredient for the detail:
Monobasic Potassium PhosphateBisphosphonates Moderate
Interaction Summary
Theoretically, taking phosphate salts with bisphosphonates might increase the risk of hypocalcemia.
Read the full Monobasic Potassium Phosphate + Risedronate Sodium interactionTiludronate DisodiumSkelid
How Tiludronate Disodium interacts with Virt-Phos 250 Neutral — through 1 ingredient. Tap an ingredient for the detail:
Monobasic Potassium PhosphateBisphosphonates Moderate
Interaction Summary
Theoretically, taking phosphate salts with bisphosphonates might increase the risk of hypocalcemia.
Read the full Monobasic Potassium Phosphate + Tiludronate Disodium interactionZoledronic AcidAclasta, Reclast, Zometa
How Zoledronic Acid interacts with Virt-Phos 250 Neutral — through 1 ingredient. Tap an ingredient for the detail:
Monobasic Potassium PhosphateBisphosphonates Moderate
Interaction Summary
Theoretically, taking phosphate salts with bisphosphonates might increase the risk of hypocalcemia.
Read the full Monobasic Potassium Phosphate + Zoledronic Acid interactionEach ingredient & the kinds of drugs it affects
For each ingredient in Virt-Phos 250 Neutral with known interactions, here are the types of medications it can affect. Open any type for the detail — or search your exact drug in the checker above.
Monobasic Potassium Phosphate
Erdafitinib (Balversa)
Taking erdafitinib with phosphate salts increases the risk of hyperphosphatemia.
Erdafitinib increases phosphate levels. It is recommended that patients taking erdafitinib restrict phosphate intake to no more than 600-800 mg daily.
Futibatinib (Lytgobi)
Taking futibatinib with phosphate salts increases the risk of hyperphosphatemia.
Futibatinib can cause hyperphosphatemia, as reported in 88% of patients in clinical studies. In addition, 77% of patients in clinical studies required use of a phosphate binder to manage hyperphosphatemia. Phosphate salts should generally be avoided by people taking this medication.
Bisphosphonates
Theoretically, taking phosphate salts with bisphosphonates might increase the risk of hypocalcemia.
Combining bisphosphonates and phosphate can cause hypocalcemia. In one report, hypocalcemic tetany developed in a patient taking alendronate (Fosamax) who received a large dose of phosphate salts as a pre-operative laxative.
Brand information
Manufacturer and brand details for Virt-Phos 250 Neutral, from the product label.
Virtus Pharmaceuticals
See all Virtus Pharmaceuticals products- Name
- Virtus Pharmaceuticals, LLC
- City
- Tampa
- State
- FL
- ZipCode
- 33619
- Phone Number
- 1-888-848-3593
Virt-Phos 250 Neutral by Virtus Pharmaceuticals: Common Questions
Does Virt-Phos 250 Neutral by Virtus Pharmaceuticals interact with any medications?
How can one product interact with so many drugs?
Where does this information come from?
What is Virt-Phos 250 Neutral used for?
What are the most common side effects?
Can I take this if I'm pregnant or breastfeeding?
Is this product safe for people with kidney disease?
How much phosphate should I be taking daily?
Written and reviewed by the HelloPharmacist editorial staff. Our editorial policy
Not sure if Virt-Phos 250 Neutral is safe with your meds?
Our pharmacists answer your medication & supplement questions — free.
Label information is sourced from the NIH Dietary Supplement Label Database and reflects the product version on file; always read your actual product label. This page is for education only and is not a substitute for professional medical advice. Confirm with your pharmacist or doctor before combining supplements and medications.
The Full Monographs Behind Virt-Phos 250 Neutral’s Ingredients
Every ingredient we hold a full HelloPharmacist monograph for — uses, evidence, safety, and the complete interaction list.
Sources & How We Checked
Virt-Phos 250 Neutral's label data comes from the NIH Dietary Supplement Label Database; the ingredient interaction data is from the Natural Medicines database, reviewed by our pharmacists.
- NIH Dietary Supplement Label Database (DSLD) — The official product label on file for this supplement.
- Natural Medicines (Therapeutic Research Center) — Evidence-graded clinical reference behind the ingredient interaction data.
Content is written and reviewed by licensed HelloPharmacist pharmacists. See our data sources and editorial standards for how this information is built and checked.
The 23 references behind this product’s interaction data
Every citation that drives the interaction findings for this product’s ingredients, from the evidence-graded Natural Medicines (TRC Healthcare) database. Open an ingredient to browse its citations — links open the study on PubMed or the publisher’s site.
Phosphate Salts 23 references
- McEvoy GK, ed. AHFS Drug Information. Bethesda, MD: American Society of Health-System Pharmacists, 1998.
- Hill AG, Teo W, Still A, et al. Cellular potassium depletion predisposes to hypokalaemia after oral sodium phosphate. Aust N Z J Surg 1998;68:856-8. PubMed
- Clarkston WK, Tsen TN, Dies DF, et al. Oral sodium phosphate versus sulfate-free polyethylene glycol electrolyte lavage solution in outpatient preparation for colonoscopy: a prospective comparison. Gastrointest Endosc 1996;43:42-8. PubMed
- Fine A, Patterson J. Severe hyperphosphatemia following phosphate administration for bowel preparation in patients with renal failure: two cases and a review of the literature. Am J Kidney Dis 1997;29:103-5. PubMed
- DiPalma JA, Buckley SE, Warner BA, et al. Biochemical effects of oral sodium phosphate. Dig Dis Sci 1996;41:749-53. PubMed
- Food and Nutrition Board, Institute of Medicine. Dietary Reference Intakes for Calcium, Phosphorus, Magnesium, Vitamin D, and Fluoride. Washington, DC: National Academy Press, 1999. Available at: http://books.nap.edu/books/0309063507/html/index.html.
- Campisi P, Badhwar V, Morin S, Trudel JL. Postoperative hypocalcemic tetany caused by Fleet Phospho-Soda preparation in a patient taking alendronate sodium. Dis Colon Rectum 1999;42:1499-501. DOI
- Ell C, Fischbach W, Layer P, Halphen M. Randomized, controlled trial of 2 L polyethylene glycol plus ascorbate components versus sodium phosphate for bowel cleansing prior to colonoscopy for cancer screening. Curr Med Res Opin. 2014 Dec;30(12):2493-503. PubMed
- Jung YS, Lee CK, Kim HJ, Eun CS, Han DS, Park DI. Randomized controlled trial of sodium phosphate tablets vs polyethylene glycol solution for colonoscopy bowel cleansing. World J Gastroenterol. 2014 Nov 14;20(42):15845-51. PubMed
- Lee SH, Lee DJ, Kim KM, Seo SW, Kang JK, Lee EH, Lee DR. Comparison of the efficacy and safety of sodium phosphate tablets and polyethylene glycol solution for bowel cleansing in healthy Korean adults. Yonsei Med J. 2014 Nov;55(6):1542-55. PubMed
- Manukyan MN, Tolan K, Severge U, Attaallah W, Kebudi A, Cingi A. Prospective randomized comparison of oral sodium phosphate and sennoside A+B calcium lavage for colonoscopy preparation. Surg Laparosc Endosc Percutan Tech. 2011 Apr;21(2):90-3. PubMed
- van Vugt van Pinxteren MW, van Kouwen MC, van Oijen MG, van Achterberg T, Nagengast FM. A prospective study of bowel preparation for colonoscopy with polyethylene glycol-electrolyte solution versus sodium phosphate in Lynch syndrome: a randomized trial. F PubMed
- Choi NK, Lee J, Chang Y, Kim YJ, Kim JY, Song HJ, Shin JY, Jung SY, Choi Y, Lee JH, Park BJ. Acute renal failure following oral sodium phosphate bowel preparation: a nationwide case-crossover study. Endoscopy. 2014 Jun;46(6):465-70. PubMed
- Brunelli SM. Association between oral sodium phosphate bowel preparations and kidney injury: a systematic review and meta-analysis. Am J Kidney Dis. 2009 Mar;53(3):448-56. PubMed
- Schaefer M, Littrell E, Khan A, Patterson ME. Estimated GFR Decline Following Sodium Phosphate Enemas Versus Polyethylene Glycol for Screening Colonoscopy: A Retrospective Cohort Study. Am J Kidney Dis. 2016 Apr;67(4):609-16. PubMed
- Ladenhauf HN, Stundner O, Spreitzhofer F, Deluggi S. Severe hyperphosphatemia after administration of sodium-phosphate containing laxatives in children: case series and systematic review of literature. Pediatr Surg Int. 2012 Aug;28(8):805-14. PubMed
- Ori Y, Rozen-Zvi B, Chagnac A, Herman M, Zingerman B, Atar E, Gafter U, Korzets A. Fatalities and severe metabolic disorders associated with the use of sodium phosphate enemas: a single center's experience. Arch Intern Med. 2012 Feb 13;172(3):263-5. PubMed
- Nam SY, Choi IJ, Park KW, Ryu KH, Kim BC, Sohn DK, Nam BH, Kim CG. Risk of hemorrhagic gastropathy associated with colonoscopy bowel preparation using oral sodium phosphate solution. Endoscopy. 2010 Feb;42(2):109-13. PubMed
- Prescribing information: BALVERSA (erdafitinib) tablets. U.S. Food and Drug Administration. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212018s000lbl.pdf. [Accessed: February 26, 2021.]
- Hung SY, Chen HC, Ke TW, et al. Noninferiority clinical trial comparing the bowel cleansing efficacy of sodium phosphate tablets (Quiklean(®)) with a polyethylene glycol/bisacodyl kit. World J Gastroenterol 2021;27(5):428-441.
- Zuluaga-Gómez M, González-Arroyave D, Ardila CM. Kounis Syndrome Secondary to Laxative Administration. Case Rep Med 2022;2022:6087176. PubMed
- Product information for Lytgobi. Taiho Pharmaceutical Co., Japan. September 2022.
- Hamilton Smith R, Eddleston M, Bateman DN. Toxicity of phosphate enemas - an updated review. Clin Toxicol (Phila) 2022;60(6):672-680. PubMed
Parts of this content are provided by the Therapeutic Research Center, LLC.
DISCLAIMER: Currently this does not check for drug-drug interactions. This is not an all-inclusive comprehensive list of potential interactions and is for informational purposes only. Not all interactions are known or well-reported in the scientific literature, and new interactions are continually being reported. Input is needed from a qualified healthcare provider including a pharmacist before starting any therapy. Application of clinical judgment is necessary.
© 2021 Therapeutic Research Center, LLC